Provided by Tiger Trade Technology Pte. Ltd.

Medicus Pharma Ltd.

0.1610
+0.00442.81%
Pre-market: 0.16190.0009+0.56%05:05 EDT
Volume:1.82M
Turnover:294.37K
Market Cap:10.17M
PE:-0.10
High:0.1684
Open:0.1575
Low:0.1550
Close:0.1566
52wk High:2.78
52wk Low:0.1440
Shares:63.18M
Float Shares:46.69M
Volume Ratio:0.98
T/O Rate:3.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6597
EPS(LYR):-2.7356
ROE:-7446.11%
ROA:-110.67%
PB:-5.77
PE(LYR):-0.06

Loading ...

Medicus Pharma Submits Teverelix Phase 2b/3 Registrational Protocol to FDA for Review

Reuters
·
Sep 29

Medicus Pharma - Anticipates Gmp Manufacturing and Study Readiness Completion Before Year-End 2026

THOMSON REUTERS
·
Sep 29

Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer

THOMSON REUTERS
·
Sep 29

Medicus Pharma - Intends to Seek Strategic Partner or Out-License Teverelix Apc Program

THOMSON REUTERS
·
Sep 29

Medicus Pharma Narrows SkinJect Development to Gorlin Syndrome in Capital-Efficient Shift

TIPRANKS
·
Sep 21

Medicus Pharma Shifts SkinJect Development Focus to Gorlin Syndrome, Drops Sporadic Basal Cell Carcinoma Program

Reuters
·
Sep 21

Medicus Pharma Announces Exclusive Development Focus for Skinject® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment

THOMSON REUTERS
·
Sep 21

Medicus Pharma - Terminates Standby Equity Purchase Agreement with Yorkville Effective Sept 11, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 14

Medicus Pharma Announces Equity-Based Bonus Share Issuance

TIPRANKS
·
Sep 11

Analysts Offer Insights on Healthcare Companies: Medicus Pharma Ltd (MDCX) and Labcorp Holdings (LH)

TIPRANKS
·
Sep 11

Medicus Pharma Issues 8,529,412 Restricted Shares in Lieu of $1.45 Million Cash Bonuses

Reuters
·
Sep 11

Medicus Selects 200 Μg SkinJect Patch as Lead Dose in Final Phase 2 Skin Cancer Study Report

Reuters
·
Sep 10

Medicus Pharma Publishes Abridged Final Phase 2 Skinject® Clinical Study Report (CSR) Results Identifying 200 ΜG D-Mna Patch as the Lead Development Dose

THOMSON REUTERS
·
Sep 10

Analysts Are Bullish on These Healthcare Stocks: IDEAYA Biosciences (IDYA), Medicus Pharma Ltd (MDCX)

TIPRANKS
·
Sep 09

Medicus Pharma Sharpened Strategy Centers on Precision Oncology and Targeted Rare Disease Programs

TIPRANKS
·
Sep 08

Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company

THOMSON REUTERS
·
Sep 08

Medicus Pharma - Cd228v Established as Principal Strategic Priority for Medicus Pharma

THOMSON REUTERS
·
Sep 08

Medicus Pharma Pivots to Precision Oncology, Prioritizing Cd228v Melanoma Proof-of-Concept Study

Reuters
·
Sep 08

U.S. Stocks on the MOVE-Gold Miners, Polestar Automotive, Nvidia

Reuters
·
Sep 03

Medicus Pharma Shares Down 20.5% Premarket; Co, Pfizer Enter Licensing Deal for Experimental Cancer Therapy

THOMSON REUTERS
·
Sep 03